Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and uneven reimbursement policies.
Ending? Only now? COVID has shown that we a) have precious little capacity left in Europe and b) are mostly reliant on base materials from China and India to keep said capacities running.
Ending? Only now? COVID has shown that we a) have precious little capacity left in Europe and b) are mostly reliant on base materials from China and India to keep said capacities running.